Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Is initiation of atorvastatin for employees a good buy for employers?

Culler SD, Weintraub WS.

Mayo Clin Proc. 2009 Dec;84(12):1059-61. doi: 10.4065/mcp.2009.0630. No abstract available.

2.

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.

Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

Mayo Clin Proc. 2009 Dec;84(12):1065-72. doi: 10.4065/mcp.2009.0298.

3.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.

Simpson RJ Jr, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

Am J Ther. 2011 Nov;18(6):436-48. doi: 10.1097/MJT.0b013e3181e4de68.

PMID:
20802306
4.

[Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].

Araujo DV, Ribeiro de Souza CP, Bahia LR, Rey HC, Dos Santos Junior B, Tura BR, Berwanger O, Buehler AM, Silva MT.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S29-32. doi: 10.1016/j.jval.2011.05.024. Portuguese.

5.

A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.

Lachaine J, Merikle E, Tarride JE, Montpetit M, Rinfret S.

Clin Ther. 2007 Mar;29(3):519-28.

PMID:
17577472
6.

Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?

Kaul P.

Eur Heart J. 2007 Jun;28(12):1405-6. Epub 2007 Jun 6. No abstract available.

PMID:
17553925
7.

The value of atorvastatin over the product life cycle in the United States.

Grabner M, Johnson W, Abdulhalim AM, Kuznik A, Mullins CD.

Clin Ther. 2011 Oct;33(10):1433-43. doi: 10.1016/j.clinthera.2011.08.014. Epub 2011 Sep 28.

PMID:
21955936
8.

[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].

Weizel A, Sawicki PT.

MMW Fortschr Med. 2004 Dec 16;146(51-52):14, 16. German. No abstract available.

PMID:
15675236
9.

What price atorvastatin?

[No authors listed]

Drug Ther Bull. 2012 Jul;50(7):73. doi: 10.1136/dtb.2012.05.0113. Epub 2012 Jul 4. No abstract available.

PMID:
22764068
10.

Generic atorvastatin and health care costs.

Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM.

N Engl J Med. 2012 Jan 19;366(3):201-4. doi: 10.1056/NEJMp1113112. Epub 2011 Dec 7. No abstract available.

11.

Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.

Hilleman DE, Wurdeman RL, Lenz TL.

Pharmacotherapy. 2001 Apr;21(4):410-5.

PMID:
11310513
12.

Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.

Lafuma A, Colin X, Solesse A.

Arch Cardiovasc Dis. 2008 May;101(5):327-32. doi: 10.1016/j.acvd.2008.05.003. Epub 2008 Jun 24.

13.

Atorvastatin: a new agent for hyperlipidemia.

Kupecz D.

Nurse Pract. 1997 Nov;22(11):87-8, 90, 93. No abstract available.

PMID:
9403876
14.

Pfizer Australia faces scrutiny over atorvastatin advertising campaign.

Sweet M.

BMJ. 2012 May 15;344:e3463. doi: 10.1136/bmj.e3463. No abstract available.

PMID:
22589531
15.
16.

Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.

Schwartz GG, Ganz P, Waters D, Arikian S.

Am J Cardiol. 2003 Nov 1;92(9):1109-12.

PMID:
14583367
17.

Potential neurological value of statins increases.

Bonetta L.

Nat Med. 2002 Jun;8(6):541. No abstract available.

PMID:
12042786
18.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-RubiĆ³ P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
19.

The cost of stroke prevention.

Samuelson RM, Levy EI, Siddiqui AH, Hopkins LN.

Stroke. 2009 Feb;40(2):e41-2; author reply e43. doi: 10.1161/STROKEAHA.108.520734. Epub 2008 Dec 18. No abstract available.

20.

Cost effectiveness of HMG-CoA reductase inhibition in Canada.

Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC.

Can J Clin Pharmacol. 2001 Spring;8(1):9-16.

PMID:
11283756

Supplemental Content

Support Center